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ABSTRACT
The staphylococcal chromosome cassette (SCC)mec types of 382 hospital-acquired methicillin-resistant
Staphylococcus aureus (HA-MRSA) isolates in Taiwan were analysed over a 7-year period (1999–2005).
There was an abrupt increase in SCCmec type IV in HA-MRSA during 2005. The molecular
epidemiology of a subset (n = 69) of HA-MRSA isolates with SCCmec types III, IV or V was
characterised and compared with that of community-acquired MRSA (CA-MRSA) (n = 26, collected
during 2005). Pulsed-ﬁeld gel electrophoresis revealed three major pulsotypes (A, B and C) and 15 minor
clones. Pulsotypes B and C, which contained isolates carrying SCCmec types IV and V, respectively,
included both CA-MRSA and HA-MRSA isolates. Among 24 toxin genes analysed, ﬁve genes had
signiﬁcant differential distribution between CA-MRSA and SCCmec type III HA-MRSA. Furthermore,
among SCCmec type IV isolates, the seb gene was detected more commonly in HA-MRSA. Analysis of
representative members of the three major pulsotypes by multilocus sequence typing revealed two
sequence types (STs), namely ST239 (SCCmecIII) and ST59 (SCCmecIV or SCCmecV). This suggests that
ST59:SCCmecIV, which is usually community-acquired, has become an important nosocomial pathogen
in the hospital studied.
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INTRODUCTION
The increasing occurrence worldwide of antibi-
otic-resistant bacteria, especially in hospitalised
patients, is a considerable concern. Established
risk-factors for hospital-acquired infection include
recent hospitalisation, surgery, residence in a
long-term care facility, dialysis, and indwelling
percutaneous medical devices and catheters [1,2].
Methicillin-resistant Staphylococcus aureus (MRSA)
is a major cause of hospital-acquired infection. As
in other countries, the prevalence of MRSA has
increased in Taiwan during the past 10 years [3],
and MRSA infections in healthy individuals
without established risk-factors have now been
documented in the community in Taiwan and
many other countries [4–8].
There are substantial differences between
community-acquired MRSA (CA-MRSA) and
hospital-acquired MRSA (HA-MRSA) in terms of
staphylococcal chromosome cassette (SCC)
mec types, distribution of toxin genes and anti-
microbial susceptibility [9–14]. CA-MRSA strains
often carry a smaller methicillin resistance
cassette (i.e., SCCmecIV or SCCmecV) and Pan-
ton–Valentine leukocidin (PVL) genes, and are
commonly more susceptible to non-b-lactam anti-
biotics [15]. In contrast, HA-MRSA strains often
carry SCCmecI, SCCmecII or SCCmecIII, and are
usually multidrug-resistant. However, the
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epidemiology of MRSA is changing, and the
emergence of healthcare-associated CA-MRSA
infections has been reported recently [16–18].
In order to better understand the changing
epidemiology of MRSA in the National Taiwan
University Hospital and the surrounding com-
munity, HA-MRSA isolates from 1999 to 2005 and
CA-MRSA isolates from 2005 were investigated
by molecular typing methods and analysed for
the presence of virulence genes.
MATERIALS AND METHODS
Bacterial isolates and case deﬁnitions
In total, 382 HA-MRSA and 26 CA-MRSA non-duplicate
clinical isolates were tested for the presence of different
SCCmec types. The 382 HA-MRSA isolates were selected
randomly from a collection of 2013 blood isolates at the
Bacteriology Laboratory of National Taiwan University
Hospital, a 2000-bed teaching hospital in northern Taiwan,
between 1999 and 2005. Only one isolate ⁄patient was
included in the study. The 26 CA-MRSA clinical isolates
were recovered from various specimens (skin and soft-tissue,
sputum, blood, urine, abscess, etc.) during 2005. None of
these isolates was obtained from a screening or surveillance
culture for MRSA. The diagnosis of infection was based on
clinical and laboratory ﬁndings. A CA-MRSA case was
deﬁned as a patient with an MRSA infection identiﬁed
within 48 h of admission without any of the following
established risk-factors: (i) a history of hospitalisation,
surgery, dialysis or residence in a long-term care facility
within 1 year of the MRSA culture; (ii) a permanent
indwelling catheter or percutaneous medical device present
at the time of culture; and (iii) a known positive culture for
MRSA before the study period [14]. An HA-MRSA case was
deﬁned as a patient with an MRSA infection identiﬁed >72 h
after admission with at least one of the above established
risk-factors.
Bacterial identiﬁcation and antimicrobial susceptibility
testing
Identiﬁcation as S. aureus was based on colony morphology,
Gram’s stain and a positive catalase reaction and slide
agglutination test result (bioMe´rieux, Marcy l’Etoile, France),
and ⁄ or results obtained with the Phoenix system (Becton
Dickinson, Sparks, MD, USA). Antimicrobial susceptibilities
were determined using the disk-diffusion method, performed
according to CLSI guidelines [19], for oxacillin, clindamycin,
erythromycin, gentamicin, minocycline, trimethoprim–sulpha-
methoxazole, vancomycin, ciproﬂoxacin and rifampicin.
Resistance to oxacillin was conﬁrmed by detecting the pres-
ence of the mecA gene by PCR [20].
SCCmec typing, agr grouping and detection of virulence
genes by PCR
Characterisation of SCCmec elements [21,22] and agr groups,
and detection of 24 speciﬁc staphylococcal virulence genes
(sea, seb, sec, sed, see, seg, seh, sei, sej, sen, seo, sem, tst, eta, etb, pvl,
lukDE, lukM, hla, hlb, hld, hlg, hlg-2 and edin), were performed
by PCR as described by Jarraud et al. [23].
Pulsed-ﬁeld gel electrophoresis, multilocus sequence
typing and spa gene typing
A subset (n = 69) of HA-MRSA isolates carrying SCCmec types
III, IV or V, and 26 CA-MRSA isolates (including all SCCmec
types), were typed by pulsed-ﬁeld gel electrophoresis (PFGE)
[24]. The 69 HA-MRSA isolates included 30 with SCCmecIII
(four isolates ⁄year in 1999–2003, and ﬁve isolates ⁄ year in 2004
and 2005), 29 with SCCmecIV (one to ﬁve isolates ⁄year in 1999–
2004, and 11 in 2005), and ten with SCCmecV (one to three
isolates ⁄year). DNA fragments were separated using a CHEF-
DR III electrophoresis system (Bio-Rad Laboratories, Hercules,
CA, USA) at 6.0 V ⁄ cm for 24 h, with pulse times ramped from 5
to 60 s. Analysis of PFGE patterns was performed using
GelCompar software (Applied Maths, Austin, TX, USA). The
genetic similarity of isolates was determined by the unweight-
ed pair-group method with arithmetic averages, and a dendr-
ogram was generated. Isolates were considered to be closely
related and to belong to the same pulsotype when their
similarity was >80%. Some of the above isolates were also
analysed by multilocus sequence typing (MLST) [25] or spa
gene typing [26].
Bacterial growth rate
An overnight culture of MRSA, grown at 37C in LB broth
(BBL; Becton Dickinson, Cockeysville, MD, USA), was diluted
1:200 with fresh LB broth and incubated at 37C with constant
agitation (230 rpm) for 6 h. Aliquots were removed, serially
diluted, and plated on Mueller–Hinton agar (BBL; Becton
Dickinson) every 30 min. The plates were incubated at 37C for
18 h and the number of colonies was then counted. The
doubling time during the log phase was calculated using
a standard method (http://textbookofbacteriology.net/
growth.html).
Bioﬁlm assays
Bioﬁlm production was evaluated by the Congo red agar
(CRA) method, with minor modiﬁcations, and the microtitre
plate method [27,28]. CRA contained 0.8 g of Congo red
(Sigma-Aldrich, St Louis, MO, USA) and various amounts (36,
18, 1 and 0.5 g) of saccharose (Merck, Darmstadt, Germany) in
1 L of brain–heart infusion agar. Isolates were inoculated on
the plate, incubated at 37C for 24 h, and kept at room
temperature overnight. Black colonies were indicative of
bioﬁlm-producing isolates, while red colonies indicated an
absence of bioﬁlm production.
RESULTS
Distribution of SCCmec types among MRSA
isolates
The distribution of SCCmec types among the
selected382HA-MRSA isolates,which represented
19% of the total MRSA isolates recovered in
the hospital between 1999 and 2005, together with
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the 26 CA-MRSA isolates from 2005, is shown in
Table 1. No SCCmecI isolate was found. SCCmecIII
was the predominant type among HA-MRSA
isolates, while most CA-MRSA isolates carried
either SCCmecIV (42%) or SCCmecV (42%). The
prevalence of SCCmecIV inHA-MRSA isolateswas
low during 1999–2004, ranging from 3-20%, but
increased to 43% in 2005. Thus, HA-MRSA shifted
from having a predominance of SCCmecIII in early
2004, to a similar frequency of isolation of
SCCmecIII and SCCmecIV in 2005.
Virulence gene analysis
The agr group and the presence of virulence genes
were compared for the 26 CA-MRSA and 69
HA-MRSA isolates with SCCmecIII, SCCmecIV or
SCCmecV (Table 2).Most isolateswere agr group 1.
Among the 24 toxin genes analysed, ﬁve genes
had signiﬁcantly different distributions between
CA-MRSA and SCCmecIII HA-MRSA. The seb
gene (which encodes staphylococcal enterotoxin
B) and the lukS–lukF (PVL) genes were detected in
62% and 50% of CA-MRSA isolates, respectively,
but in none of the SCCmecIII HA-MRSA isolates.
The hlg gene, which encodes b-haemolysin com-
ponents A, B and C, was detected more often in
CA-MRSA than in SCCmecIII HA-MRSA. In con-
trast, the lukDE gene and the sea gene (which
encodes staphylococcal enterotoxin A) were com-
monly seen in SCCmecIII HA-MRSA (100% and
77%, respectively), but were detected rarely in
CA-MRSA (15% and 12%, respectively). Further-
more, the seb gene was detected more commonly
in SCCmecIV HA-MRSA than in SCCmecIV
CA-MRSA. There was no difference between
SCCmecV CA-MRSA and SCCmecV HA-MRSA
with respect to the occurrence of the 24 virulence
genes.
Characteristics of patients
CA-MRSA patients were younger than HA-MRSA
patients with SCCmecIII and SCCmecIV (median
age 37 years vs. 59 and 58 years, respectively),
and most CA-MRSA patients were aged
<10 years. In contrast, HA-MRSA infections with
SCCmecIII, SCCmecIV or SCCmecV were seen
mostly in the elderly. Hospital-acquired infection
with MRSA carrying SCCmecIV or SCCmecV was
more common among male patients (n = 29;
74%), while infection with CA-MRSA was more
common among females (n = 18; 69%). The most
common underlying disease associated with
SCCmecIII HA-MRSA was pulmonary disease,
followed by cardiovascular disease. Compared
with the SCCmecIII group, patients with SCC
mecIV HA-MRSA were associated with a higher
frequency of cardiovascular disease, and a lower
frequency of pulmonary or liver disease.
Cardiovascular disease was more common in
the SCCmecIV HA-MRSA group (n = 17; 58%)
than in the SCCmecV HA-MRSA group (n = 1;
10%).
PFGE, MLST, spa gene typing and antimicrobial
susceptibility
PFGE analysis grouped the 95 MRSA isolates into
three major clusters (pulsotypes), A, B and C,
which accounted for 77% of all isolates, and 15
minor clones (Fig. S1; see Supplementary mater-
ial). Among the 30 SCCmecIII HA-MRSA isolates,
25 (83%) belonged to pulsotype A. The ﬁve
remaining isolates belonged to either pulsotype
D or pulsotype E. Eight (73%) of 11 SCCmecIV
CA-MRSA isolates were grouped into pulsotype
B, and 23 (79%) of 29 SCCmecIV HA-MRSA
isolates were also closely related to pulsotype B.
Ten (91%) of 11 SCCmecV CA-MRSA isolates and
four (40%) of ten HA-MRSA isolates carrying
SCCmecV were clustered together in pulsotype C.
These results suggest that pulsotype B and C
isolates carrying SCCmec types IV and V, respect-
ively, had spread between the community and the
hospital.
Antimicrobial susceptibilities were compared
for SCCmecIII and SCCmecIV ⁄V isolates. All were
susceptible to vancomycin, but most SCCmecIII
Table 1. Distribution of SCCmec types among 382 hospi-
tal-acquired methicillin-resistant Staphylococcus aureus
(MRSA) isolates between 1999 and 2005, and 26 commu-




SCCmec types, n (%)
II III IV V Total
Hospital-acquired 1999 5 (9) 35 (65) 11 (20) 3 (6) 54
2000 2 (3) 42 (72) 9 (16) 5 (9) 58
2001 5 (9) 46 (79) 6 (10) 1 (2) 58
2002 8 (13) 49 (82) 2 (3) 1 (2) 60
2003 7 (13) 42 (75) 2 (4) 5 (9) 56
2004 4 (7) 42 (75) 8 (14) 2 (4) 56
2005 2 (5) 19 (48) 17 (43) 2 (5) 40
Community-acquired 2005 1 (4) 3 (12) 11 (42) 11 (42) 26
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HA-MRSA isolates were resistant to
multiple drugs, e.g., ciproﬂoxacin (97%),
clindamycin (90%), erythromycin (100%),
gentamicin (100%), minocycline (77%) and
trimethoprim–sulphamethoxazole (97%). The
SCCmecIV ⁄V isolates, regardless of origin, were
susceptible to numerous antimicrobial agents,
including ciproﬂoxacin (92% susceptible),
minocycline (95% susceptible) and trimethoprim–
sulphamethoxazole (95% susceptible). Suscepti-
bilities to clindamycin, erythromycin and
gentamicin for SCCmecIV ⁄V HA-MRSA isolates
were 13%, 8% and 59%, respectively.
Two sequence types (STs), ST239 and ST59,
were identiﬁed by MLST of randomly selected
isolates from the three major pulsotypes A, B and
C. Overall, the results were in agreement with
those obtained following PFGE. Thus, all ﬁve
isolates from pulsotype A with SCCmecIII
belonged to ST239. Isolates from pulsotypes B
and C with SCCmecIV or SCCmecV, whether
isolated from community or hospital, belonged
to ST59.
Isolates representing the three major clones
were also examined by spa gene typing. ST239
isolates shared the spa repeat codes WGKAOMQ,
while ST59 isolates shared ZDMDMOB.
Growth rate and bioﬁlm activity
The reason for the abrupt increase in the number of
SCCmecIV MRSA infections during 2005 in this
hospital is unclear. As a shorter doubling time
and ⁄ or increased bioﬁlm formationmayplay a role
in enhancing the ecological ﬁtness of SCCmecIV
isolates (leading to an increased incidence of
infection), the growth rate was measured by
calculating the doubling time during exponential
Table 2. Comparison of virulence genes and patient characteristics for community-acquired methicillin-resistant
Staphylococcus aureus (CA-MRSA) and hospital-acquired MRSA (HA-MRSA)
Virulence gene or patient characteristics


















1 4 9 11 24 (92%) 27 27 10 64 (93%)
2 0 1 0 1 (4%) 3 1 0 4 (6%)
3 0 1 0 1 (4%) 0 1 0 1 (1%)
Staphylococcal enterotoxin genes
sea 3 0 0 3 (12%) 23 3 0 26 (38%)
seb 0 6 10 16 (62%) 0 27 9 36 (52%)
sec 0 1 0 1 (4%) 0 1 0 1 (1%)
sed 0 0 0 0 0 0 0 0
see 0 0 0 0 3 0 0 3 (4%)
seg 0 2 1 3 (12%) 0 1 0 1 (1%)
seh 0 1 0 1 (4%) 0 1 0 1 (1%
sei 0 2 1 3 (12%) 0 1 0 1 (1%)
sej 0 0 0 0 0 0 0 0
sem 1 1 0 2 (8%) 0 2 0 2 (2%)
sen 0 3 1 4 (15%) 1 1 0 2 (2%)
seo 1 2 1 4 (15%) 0 1 0 1 (1%)
tst 0 0 0 0 0 1 0 1 (1%)
Exfoliative toxin genes
eta 1 0 0 1 (4%) 1 0 0 1 (1%)
etb 1 0 0 1 (4%) 0 0 0 0
Leukocidin genes
lukPVSF 0 2 11 13 (50%) 0 2 9 11 (16%)
lukED 3 1 0 4 (15%) 30 1 1 32 (46%)
lukM 0 0 0 0 0 0 0 0
Haemolysin genes
hla 4 11 11 26 (100%) 30 29 10 69 (100%)
hlb 4 10 11 25 (96%) 29 22 10 61 (88%)
hld 4 11 11 26 (100%) 30 29 10 69 (100%)
hlg 3 10 9 22 (85%) 11 29 10 49 (71%)
hlg-2 3 9 10 22 (85%) 30 28 10 68 (98%)
Other
edin 0 0 0 0 0 0 0 0
Patient characteristics
Diabetes mellitus 0 3 1 4 (15%) 8 9 0 17 (25%)
Cardiovascular disease 1 1 1 3 (12%) 15 17 1 33 (48%)
Pulmonary disease 1 0 1 2 (8%) 17 8 2 27 (39%)
History of malignancy 1 1 0 2 (8%) 10 8 3 21 (30%)
History of liver disease 0 0 0 0 6 2 0 8 (12%)
Previous antimicrobial chemotherapy 0 0 0 0 22 21 ⁄ 27 5 ⁄ 9 48 ⁄ 66 (73%)
Previous invasive procedure 0 0 0 0 20 18 ⁄ 27 3 ⁄ 9 41 ⁄ 66 (62%)
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growth for selected isolates with different SCCmec
types. Some, but not all, isolates with SCCmecIV
grew slightly faster than MRSA isolates carrying
other SCCmec types (Table 3).
Isolates carrying different SCCmec types were
also tested for their bioﬁlm (or slime-producing)
ability by the modiﬁed CRA method and micro-
titre plate method. All isolates examined formed
black colonies on CRA containing saccharose at
concentrations of 36, 18 or 1 g ⁄L, and several
isolates were still able to form black colonies at a
very low saccharose concentration of 0.5 g ⁄L. A
wide range of bioﬁlm-forming ability was detected
among isolates by the microtitre method
(Table 3).
DISCUSSION
It has been reported previously that SCCmecIII is
the main type of HA-MRSA, while SCCmecIV and
SCCmecV are the main types of CA-MRSA in
Taiwan and other Asian countries [29–31]. In the
present study, the distribution of SCCmec types
remained unchanged between 1999 and 2004, but
therewas an increase inSCCmecIVduring2005, to a
level similar to that of SCCmecIII in HA-MRSA.
Wisplinghoff et al. [33] reported a decreasing pre-
valence of SCCmecIII in Germany between 1984
and 1998, while de A Trindade et al. [17] reported a
high (95%) prevalence of SCCmecIV among
nosocomial bloodstream isolates of MRSA collec-
tedduring a7-monthperiod inBrazil.An increased
incidence of MRSA clones carrying SCCmecIV has
been reported during recent years in Norway [34].
A recent study from Taiwan also demonstrated a
high (40%) prevalence of SCCmecIV among
HA-MRSA isolates [35]. These studies implied that
there is an increasing incidence of SCCmecIV and a
decreasing incidence of SCCmecIII.
High morbidity and mortality caused by
CA-MRSA infections have raised concerns world-
wide in recent years [36]. Several previous studies
have compared cases of CA-MRSA and HA-
MRSA infection in terms of clinical characteristics,
antibiotic susceptibility and genetic background
[10,37]. In agreement with these reports, the
results of the present study showed that cases of
CA-MRSA infection occurred most frequently
among children, females and patients with
diabetes, while HA-MRSA infection occurred
signiﬁcantly more often among the elderly and
patients with underlying cardiovascular or
bronchopulmonary disease.
The present study revealed that three genes
(seb, pvl and hlg) were present more frequently in
CA-MRSA than in SCCmecIII HA-MRSA isolates.
However, within SCCmecIV isolates, the seb gene
was detected at a higher frequency in HA-MRSA
Table 3. Growth rate and bioﬁlm
assay for methicillin-resistant Sta-









Colony phenotype on Congo
red agar
Microtitre plate





HA8270 II 30.9 ± 4.97 Black Red 0.308 ± 0.044
HA5584 II 32.7 ± 1.28 Black Red 0.180 ± 0.028
HA2370 III 32.7 ± 3.40 Black Red 0.196 ± 0.033
HA6436 III 34.2 ± 1.68 Black Black 0.441 ± 0.085
HA9471 III ND Black Red ND
HA163 III ND Black Red ND
HA819 III ND Black Red ND
HA6688 III ND Black Red ND
CA748 IV 31.3 ± 0.12 Black Red 0.185 ± 0.008
CA1576 IV 34.5 ± 1.50 Black Red 0.174 ± 0.057
CA5704 IV ND Black Red ND
CA4939 IV ND Black Red ND
CA4136 IV ND Black Black ND
HA586 IV 33.2 ± 0.81 Black Red
(dry and rough)
0.202 ± 0.043
HA312 IV 29.6 ± 1.40 Black Red 0.171 ± 0.020
HA1436 IV 33.1 ± 1.89 Black Black 0.427 ± 0.098
HA3850 IV 27.2 ± 1.87 Black Black 0.418 ± 0.032
HA8993 IV ND Black Black ND
CA7796 V 28.6 ± 4.32 Black Red 0.167 ± 0.068
CA7584 V 30.5 ± 2.25 Black Black 0.113 ± 0.015
HA2841 V 33.3 ± 3.85 Black Black 0.183 ± 0.039
HA3165 V 33.8 ± 2.69 Black Red 0.095 ± 0.049
aAverage of data from three experiments.
HA, hospital-acquired; CA-community-acquired; ND, not done.
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than in CA-MRSA isolates. The signiﬁcance of this
difference is unclear. The seb gene has been found
frequently among S. aureus isolates from children
with staphylococcal toxic shock syndrome [38].
The PVL genes are associated frequently with
community-acquired staphylococcal skin infec-
tions and necrotising pneumonia [39,40]. In the
present study, half of the CA-MRSA isolates
carried the PVL genes, and among 13 patients
with PVL-positive CA-MRSA infection, 62% had
skin infections or necrotising pneumonia. How-
ever, PVL genes were also detected in most (9 ⁄ 10)
SCCmecV HA-MRSA isolates. Among 11 patients
with PVL-positive HA-MRSA infections, ﬁve
were associated with skin infections or necrotis-
ing pneumonia. This indicates that PVL may also
play a role in HA-MRSA infections. However, the
study compared a selection of non-consecutive
HA-MRSA infections with consecutive CA-MRSA
infections, which may lead to a potential bias in
terms of differences in virulence factors or patient
variables, which is a limitation of this study.
Previous studies have shown that CA-MRSA
strains, which are generally only resistant to
b-lactam antibiotics, are typically more suscept-
ible to antibiotics than HA-MRSA strains [10–17].
In the present study, the CA-MRSA isolates were
resistant not only to b-lactam antibiotics, but also
to erythromycin, clindamycin and gentamicin. In
agreement with other reports from Taiwan,
SCCmecIII HA-MRSA isolates were resistant to
multiple drugs, including erythromycin, clinda-
mycin, gentamicin, trimethoprim–sulphameth-
oxazole, minocycline and ciproﬂoxacin [8,30].
Moreover, the susceptibility patterns of SCCmecIV
or SCCmecV HA-MRSA isolates were similar to
those of the CA-MRSA isolates, which were
usually susceptible to minocycline, ciproﬂoxacin
and trimethoprim–sulphamethoxazole, 59% sus-
ceptible to gentamicin, and mostly resistant to
erythromycin and clindamycin.
SCCmecIV CA-MRSA is usually considered to
be genetically heterogeneous. Unexpectedly,
SCCmecIV-containing CA-MRSA and HA-MRSA
isolates in the present study were shown to be
clonally related by PFGE, and shared the same
ST59 genetic background. In addition, the
susceptibility patterns of SCCmecIV or SCCmecV
HA-MRSA isolates were the same as those of
CA-MRSA isolates. Although CA-MRSA isolates
usually have distinct molecular features
compared with HA-MRSA isolates [17,18], the
genotype of the SCCmecIV or SCCmecV CA-MRSA
isolates was similar to that of HA-MRSA isolates
with SCCmecIV or SCCmecV (clones B and C),
respectively. Thus, in addition to the existing
clone A (ST239, SCCmecIII) in the hospital, clones
B (ST59, SCCmecIV) and C (ST59, SCCmecV),
which were relatively more susceptible, had
spread in both the community and the hospital.
Although the origin of these clones could not be
traced to the hospital or community (because
CA-MRSA isolates were not collected before
2005), the clone that was SCCmecIV or SCCmecV,
ST59, PVL-positive, and that was usually consid-
ered to be community-acquired, appeared to have
become nosocomial. The ST239 type (clonal com-
plex (CC) 239, regarded as a lineage within CC8)
resembles the Hungarian clone; this is a common
MLST type among HA-MRSA isolates in Taiwan
[31] and other Asian countries [32], and was
reported to be the earliest predominant ST
between 1984 and 1988 in Germany [33]. ST59
(CC59) is the predominant CA-MRSA clone with
SCCmecIV or SCCmecV in Taiwan [8], but has been
described infrequently in other countries [34].
The possible reasons for the dramatic increase
in the prevalence of SCCmecIV HA-MRSA during
2005 in this hospital remain unclear. It has been
suggested previously that CA-MRSA may have
enhanced ecological ﬁtness because of a shorter
doubling time than HA-MRSA [41]. Different
growth rates were revealed for SCCmecIV MRSA
isolates, and some multiplied faster than SCC
mecIII HA-MRSA isolates. Moreover, patients
with SCCmecIV HA-MRSA infections were found
to have a higher incidence of underlying cardio-
vascular disease and prosthetic devices. This
suggests that bioﬁlm-producing ability, together
with a rapid growth rate, may enhance the ﬁtness
of SCCmecIV MRSA.
Although CA-MRSA is responsible for commu-
nity-acquired infections, the appearance of
CA-MRSA isolates causing nosocomial infections
is a more recent phenomenon. The present data
suggest an increasing incidence of SCCmecIV
MRSA, which may become one of the dominant
types in hospitals in the future. In addition, clones
B and C appear to have spread between the
community and the hospital. Continued surveil-
lance of the ST59:SCCmecIV and ST59:SCCmecV
clones, as well as analysis of their virulence
factors, will therefore be important for monitoring
this spread.
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